Cash Position: Ended Q1 2024 with $714.3 million in cash, cash equivalents, and marketable securities, down from $806.4 ...

Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the ...

Agios Pharmaceuticals will present their latest quarterly figures on May 2.Wall Street predict expect Agios Pharmaceuticals will report losses ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $81.5 million in its first quarter. The Cambridge, Massachusetts-based company said it ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago. These ...

Agios Pharmaceuticals Inc.’s fourth-quarter and full-year 2023 financial report in mid-February highlighted further prospects with Pyrukynd (mitapivat), the pyruvate kinase activator for hemolytic ...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular ...

In a nutshell, Agios Pharmaceuticals Inc (AGIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that ...

AGIO stock has gone up by 1.36%, with a monthly decline of -1.06% and a quarterly surge of 37.64%. The volatility ratio for the week is 3.63%, and the volatility levels for the last 30 days are 3.67% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...